BeyondSpring (BYSI) insiders report 14.1% each; trust transfers disclosed
BeyondSpring Inc. (BYSI) insiders Lan Huang and Linqing Jia each reported beneficial ownership of 5,787,906 shares, representing 14.1% of the company's outstanding shares as of March 31, 2026. This disclosure was made in an Amendment No. 9 to a Schedule 13G/A filing, detailing ownership through various entities, trusts, and proxies, and clarifying shared voting and dispositive powers. The filing also revealed recent intra-family trust transfers of 260,582 and 253,465 shares.
MAY 14·Stock Titan▼
BeyondSpring (NASDAQ: BYSI) swings to $6.7M net loss as SEED ops weigh
BeyondSpring (NASDAQ: BYSI) reported a consolidated net loss of $6.7 million for Q1 2026, a significant swing from a $1.2 million net income in Q1 2025, primarily due to a $4.3 million loss from discontinued SEED operations and the absence of a $7.0 million gain from a SEED share sale seen in the prior year. The company's continuing operations recorded a $2.4 million net loss, with research and development expenses increasing while general and administrative costs decreased. BeyondSpring ended the quarter with $7.9 million in cash and short-term investments from continuing operations, and expects additional inflows from future SEED preferred share sales, with management exploring various financing and strategic alternatives.
MAR 30·The Manila Times▲
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company, announced that it will present a poster on Plinabulin and ADC combination at the 2026 AACR Annual Meeting. The presentation, titled "Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor," will detail how Plinabulin enhances the effectiveness of antibody-drug conjugates. This aims to highlight its potential in improving cancer treatment outcomes, particularly in restoring tumor sensitivity to checkpoint inhibitors.
